论文部分内容阅读
根据美国临床肿瘤学会(ASCO)发布的暂行临床意见(PCO),在个体化分析的基础上,应当将男性的预期寿命作为判断前列腺特异性抗原(PSA)筛查是否合理的依据。具体而言,对于预期剩余寿命不足10年的男性,ASCO同意2012年5月美国预防服务工作组(USPSTF)指南的建议,即PSA筛查的风险大于收益。而对于预期寿命较长的男性,ASCO专家组共同主席Ethan Basch博士建议,“临床医生应当与患者讨论PSA筛查是否合理。PSA筛查可能挽救生命,但也伴随危害,包括不必要的活检、手术或放疗及其所导致的并发症”。
According to the Interim Clinical Opinion (PCO) issued by the American Society of Clinical Oncology (PCCO), based on individualized analysis, the life expectancy of males should be used as the basis for judging whether screening of prostate specific antigen (PSA) is reasonable. Specifically, for men expecting less than 10 years of remaining life, ASCO agrees with the USPSTF guidelines of May 2012 that PSA screening outweighs the benefits. For men with long life expectancy, Ethan Basch, MD, co-chair of the ASCO expert group, recommends that “clinicians should discuss with patients about the plausibility of PSA screening, which may save lives, but also harm, including unnecessary biopsies , Surgery or radiotherapy and the complications it causes. ”